Pfizer: Inflammatory Bowel Diseases trials

The registry lists 15 Inflammatory Bowel Diseases studies with Pfizer as lead sponsor. 0 are open to participants now and 9 have results posted.

Phase 1 7Phase 2 3Phase 3 2Phase 4 2No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Learn About Study Medicine Called PF-07261271 in Healthy PeopleCompletedNCT05536440Phase 1Results posted
• Evaluation of the Pharmacokinetics, Safety and Tolerability of Single Dose of PF-06480605 in Chinese Healthy ParticipantsCompletedNCT05107492Phase 1Results posted
• A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's DiseaseTerminatedNCT04173273Phase 2/3Results posted
• Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel DiseaseCompletedNCT03801928Results posted
• A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable RemissionTerminatedNCT03281304Phase 4Results posted
• Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal ManifestationsTerminatedNCT03139032Phase 2Results posted
• Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel DiseaseCompletedNCT02539368Results posted
• A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative ColitisCompletedNCT01458574Phase 3Results posted
• Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical PatientsTerminatedNCT00445328Phase 4Results posted
• A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative ColitisTerminatedNCT05549323Phase 1
• Distribution of a Single IV Dose Of [124I]-Pf 06687234 and Pf 06687234 Assessed With PET-CT Imaging In Moderate To Severe Ulcerative Colitis and Crohn's DiseaseWithdrawnNCT03414788Phase 1
• Bioavailability Study Of PF-06651600 In Healthy SubjectsCompletedNCT02684760Phase 1
• Safety and Pharmacokinetic Study of PF-06651600 in Healthy VolunteersCompletedNCT02309827Phase 1
• Study Evaluating rhIL-11 in Active Crohn's DiseaseCompletedNCT00040521Phase 2
• Study Evaluating rhIL-11 in Left-Sided Ulcerative ColitisTerminatedNCT00038922Phase 1